Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Bartolacci C, et al. Among authors: lorenzini d. Nat Commun. 2022 Aug 8;13(1):4640. doi: 10.1038/s41467-022-32459-x. Nat Commun. 2022. PMID: 35941179 Free PMC article. No abstract available.
Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components.
Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. Soundararajan R, et al. Among authors: lorenzini d. Cancers (Basel). 2022 Jun 30;14(13):3233. doi: 10.3390/cancers14133233. Cancers (Basel). 2022. PMID: 35805010 Free PMC article.
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Bartolacci C, et al. Among authors: lorenzini d. Nat Commun. 2022 Jul 26;13(1):4327. doi: 10.1038/s41467-022-31963-4. Nat Commun. 2022. PMID: 35882862 Free PMC article.
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Johnson B, et al. Among authors: lorenzini d. J Immunother Cancer. 2022 Aug;10(8):e005332. doi: 10.1136/jitc-2022-005332. J Immunother Cancer. 2022. PMID: 36007963 Free PMC article. Clinical Trial.
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.
Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Kanikarla Marie P, et al. Among authors: lorenzini d. Clin Cancer Res. 2021 Jun 1;27(11):3039-3049. doi: 10.1158/1078-0432.CCR-21-0163. Epub 2021 Apr 2. Clin Cancer Res. 2021. PMID: 33811152 Free PMC article. Clinical Trial.
A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei.
Kusamura S, Busico A, Conca E, Capone I, Agnelli L, Lorenzini D, Brich S, Angelini M, Volpi CC, Trupia DV, Lagano V, Torelli T, Gloghini A, Baratti D, Guaglio M, Milione M, Deraco M, Perrone F. Kusamura S, et al. Among authors: lorenzini d. Biomedicines. 2023 Jul 20;11(7):2049. doi: 10.3390/biomedicines11072049. Biomedicines. 2023. PMID: 37509688 Free PMC article.
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples.
Capone I, Bozzi F, Dagrada GP, Verderio P, Conca E, Busico A, Testi MA, Monti V, Duca M, Proto C, Damian S, Piccolo A, Perrone F, Tamborini E, Devecchi A, Collini P, Lorenzini D, Vingiani A, Agnelli L, Pruneri G. Capone I, et al. Among authors: lorenzini d. Explor Target Antitumor Ther. 2022;3(5):582-597. doi: 10.37349/etat.2022.00102. Epub 2022 Oct 27. Explor Target Antitumor Ther. 2022. PMID: 36338518 Free PMC article.
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.
Tabanelli V, Melle F, Motta G, Mazzara S, Fabbri M, Agostinelli C, Calleri A, Del Corvo M, Fiori S, Lorenzini D, Cesano A, Chiappella A, Vitolo U, Derenzini E, Griffin GK, Rodig SJ, Vanazzi A, Sabattini E, Tarella C, Sapienza MR, Pileri SA. Tabanelli V, et al. Among authors: lorenzini d. Blood Adv. 2022 Aug 9;6(15):4634-4644. doi: 10.1182/bloodadvances.2022007046. Blood Adv. 2022. PMID: 35767735 Free PMC article.
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Brambilla M, Beninato T, Piemontese A, Mazzeo L, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, Prelaj A, Ferrara R, Proto C, Lo Russo G, Pizzutilo EG, Ganzinelli M, Grande I, Capone I, Di Mauro RM, Conca E, Dumitrascu AD, Zanella C, Leporati R, Rota S, Garassino MC, Marchetti P, de Braud FM, Occhipinti M. Brambilla M, et al. Among authors: lorenzini d. Clin Lung Cancer. 2023 Nov;24(7):631-640.e2. doi: 10.1016/j.cllc.2023.08.004. Epub 2023 Aug 23. Clin Lung Cancer. 2023. PMID: 37775370 Free article.
64 results